Stephen Liu, MD

Benjamin Weinberg, MD, FACP

GI Oncology Now

Drs. Stephen Liu and Benjamin Weinberg of Lombardi Comprehensive Cancer Center elaborate on the prevalence of NRG1 gene fusions in pancreatic ductal adenocarcinoma (PDAC), strategies they recommend for effectively identifying these fusions in clinical practice, and observed response rates and survival outcomes for PDAC patients treated with zenocutuzumab in <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2405008" target="_blank" rel="noopener">a recent NEJM publication</a>.View their continued comments on <a href="https://www.gioncologynow.com/post/zenocutuzumab-for-pancreatic-cancer-toxicity-concerns-and-ongoing-research" target="_blank" rel="noopener">Toxicity Concerns and Ongoing Research</a>.

Yelena Janjigian, MD

KEYNOTE-811: Dr. Yelena Janjigian on Pembrolizumab's FDA Approval for Gastric/GEJ Cancer

Gastric Cancer

Ashwin Somasundaram, MD

Investigating Ipi/Nivo With Panitumumab in MSS mCRC

Colorectal Cancer

Emily Menendez

Zenocutuzumab Safety, Efficacy for NRG1 Fusion-Positive Pancreatic Cancer: Low-Grade AEs

Pancreatic Cancer

Latest News

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Pancreatic Cancer

Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

GU Oncology Now

Lung Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Bile Duct

Colorectal

Esophageal

Gastric

GEP-NETs

GIST

Liver

Pancreatic

Conference Coverage

Video Insights

Roundtable